DESTINY TRIAL (Inspiron x Biomatrix)

Exclusion Criteria

• •1. Women of childbearing age with no history of surgical sterilization;
• •2. Myocardial infarction with Q wave occurred in the last 48 hours before the index procedure;
• •3. Myocardial infarction with or without Q wave with cardiac markers even at high levels;
• •4. Ejection fraction \< 30%;
• •5. Impaired renal function (creatinine\> 2.0 mg / dl) or calculated creatinine clearance \< 60 ml / min;
• •6. Platelet count \<100,000 cells/mm3 or \> 700,000 cells/mm3;
• •7. Total leukocyte count \<3000 cells/mm3;
• •8. Documented or suspected liver disease (including laboratory evidence of hepatitis);
• •9. Heart transplant recipient;
• •10. Known allergies to aspirin, clopidogrel, ticlopidine, paclitaxel, sirolimus, heparin or stainless steel;
• •11. Patient with a life expectancy less than 12 months;
• •12. Any significant medical condition which in the opinion of the investigator would interfere with the ideal of patient participation in this study;
• •13. Participation in other research in the last 12 months, unless there is direct benefit to the research subject;
• •14. Coronary angioplasty (with or without stenting) for less than 6 months anywhere in the target vessel;
• •15. Coronary angioplasty (with or without stenting) prior to any time in that segment Diste less than 5 mm (proximal or distal) of the lesion;
• •16. Coronary angioplasty (with or without stenting) scheduled in the first 12 months after the index procedure in any segment of the target vessel.
• •1. Restenotic target lesion;
• •2. Need for treatment for more than one lesion in the same vessel;
• •3. Need for treatment with three or more lesions in the same procedure;
• •4. Target vessel diameter \<2.5 mm or\> 3.5 mm (visual);
• •5. Target lesion long not susceptible to treatment with a single stent to 29mm in length, according to the judgment of the operator;
• •6. Lesion of the coronary artery unprotected ( \> 50% stenosis);
• •7. Angiographic thrombus;
• •8. Target lesion in surgical graft;
• •9. Total occlusion (TIMI anterograde flow 0 or 1);
• •10. Ostial lesion;
• •11. The target lesion bifurcation with side branch that may require intervention during the procedure, with or without stenting;
• •12. Injuries that are impossible to anticipate predilatation successfully or that is necessary to use rotablator;
• •13. The target vessel with excessive tortuosity.